Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR408701 plus pembrolizumab versus pembrolizumab alone in CEACAM5- and PD-L1-positive advanced non-squamous non-small cell lung cancer
2020-000035-50Phase 2Active
- Sponsor
- Sanofi
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing SAR408701 plus pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Number of participants with study drug-related dose-limiting toxicities. Started Apr 2020; status: active.
02
Drugs
tusamitamab ravtansinepembrolizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2020-000035-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000035-50.